Kidney transplantation and metabolic syndrome
Authors:
Ivana Dedinská 1; Juraj Miklušica 1; Ľudovít Laca 1; Blažej Palkoci 1; Denisa Osinová 2; Pavel Makovický 3; Peter Galajda 3; Marián Mokáň 3
Authors place of work:
Chirurgická klinika a transplantačné centrum, Jesseniova LF UK a UN Martin
1; Klinika anesteziológie a intenzívnej medicíny, Jesseniova LF UK a UN Martin
2; I. interná klinika, Jesseniova LF UK a UN Martin
3
Published in the journal:
Forum Diab 2016; 5(2): 94-98
Category:
Topic
Summary
Aims:
The metabolic syndrome developed after kidney transplantation is the result of several factors which are identical with the risk factors in normal population, however, also some factors typical for the transplanted patients – especially the effects of immunosuppressive therapy.
Material and Methods:
In the group of 268 patients after kidney transplantation, which had no type 1 or type 2 diabetes mellitus before transplantation, we identified patients with metabolic syndrome(based on IDF criteria), 12 months from the kidney transplantation. In all patients, we recorded the following parameters: age at the time of transplantation, type of immunosuppression, waist measure, the value of triacylglycerols, the value of HDL cholesterol, presence of arterial hypertension, and the value of glycaemia in fasting state (or presence of diabetes mellitus). The group of patients was divided into the control group and the group of patients with metabolic syndrome.
Results:
The average age of patients was 46.1 ± 11.6 years. The control group included 149 patients (55.6 %), and we identified the metabolic syndrome in 119 patients (44.4 %). The patients with metabolic syndrome were significantly older (p < 0.0001), had significantly larger waist (both the entire group and the males and females) p < 0.0001. The females with metabolic syndrome had significantly lower value of HDL-cholesterol (p = 0.0013), and significantly higher number of patients with metabolic syndrome had hyperglycaemia in fasting state or diabetes mellitus (p = 0.0006).
Conclusion:
By controlling the weight and waist, we may identify the risk patients for development of metabolic syndrome after kidney transplantation.
Key words:
immunosuppressive therapy – kidney transplantation – metabolic syndrome
Zdroje
1. Galajda, P, Mokáň M. Problematika etiopatogenézy a diagnostiky metabolického syndrómu. Diabetes a obezita 2004; 4(7): 39–49.
2. Pearson TA, Mensah GA, Alexander RW et al. [AHA/CDC Scientific Statement]. Markers of inflammation and cardiovascular disease: application to clinical and public health practice. Circulation 2003; 107(3): 499–511.
3. Dedinská I, Laca L, Miklušica J et al. Twelve-Month and Five-Year Analyses of Risk Factors for New-Onset Diabetes After Transplantation in a Group of Patients Homogeneous for Immunosuppression. Transplant Proc 2015; 47(6): 1831–1839.
4. Laca ľ, Olejník J, Vician M et al. The effect of occlusive techniques on the short-term prognosis after liver resections. Hepatogastroenterology 2006; 53(70): 576–579.
5. Goldsmith D, Pietrangeli CE. The metabolic syndrome following kidney transplantation. Kidney Int Suppl 2010; (118): S8-S14.
6. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004; 89(6): 2548–2556.
7. Karlsson AF, Berglund L, Berne CH. Low serum adiponectin concentrations are associated with insulin sensitivity independent of obesity in Sudanese subjects with type 2 diabetes mellitus. Diabetol Metabolic Syndr 2013; 5(1): 15.
8. Ekberg H, Tedesco-Silva H, Demirbas A et al. [ELITE-Symphony Study]. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357(25): 2562–2575.
9. Noël C, Abramowicz D, Durand D et al. Daclizumab versus antithymocyte globulin in high-immunological-risk renal transplant recipients. J Am Soc Nephrol 2009; 20(6): 1385–1392.
10. van Gelder T, Le Meur Y, Shaw LM et al. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit 2006; 28(2): 145–154.
11. Pascual J, Galeano C, Royuela A et al. A systematic review on steroid withdrawal between 3 and 6 months after kidney transplantation. Transplantation 2010; 90(4): 343–349.
12. Hricik DE. Metabolic Syndrome in KidneyTransplantation: Management of Risk Factors. Clin J Am Soc Nephrol 2011; 6(7): 1781–1785.
13. Meier-Kriesche HU, Arndorfer JA, Kaplan B. Theimpact of body mass index on renal transplant outcomes: A significant independent risk factor for graft failure and patient death. Transplantation 2002; 73(1): 70–74.
14. Clunk JM, Lin CY, Curtis JJ. Variables affecting weight gain in renal transplant recipients. Am J Kidney Dis 2001; 38(2): 349–353.
15. Potluri K, Hou S. Obesity in kidney transplant recipients and candidates. Am J Kidney Dis 2010; 56(1): 143–156.
16. Dedinská I, Laca Ľ, Miklušica M et al. Waist circumference as anindependent risk factorfor NODAT. Ann Transplant 2015; 20: 154–159. Dostupné z DOI: <http://dx.doi.org/10.12659/AOT.892067>
17. Cashion AK, Sanchez ZV, Cowan PA et al. Changes in weight during the first year after kidney transplantation. Prog Transplant 2007; 17(1): 40–47.
18. Leavey SF, McCullough K, Hecking E et al. Body mass index and mortality in ‘healthier’ as comparedwith ‘sicker’ haemodialysis patients: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2001; 16(12): 2386–2394.
19. Salahudeen AK. Obesity and survival on dialysis. Am J Kidney Dis 2003; 41(5): 925–932.
20. Zeleňák K, Šinák I, Janík J et al. Bleeding in acute pancreatitis treated by transcatheter arterial embolization with ethylen-vinyl alcohol copolymer (ONYX). VASA 2012; 41(5): 380–382.
21. Dedinská I, Kantárová D, Laca et al. Metabolické účinky imunosupresívnej liečby. Diabetes a obezita 2014; 14(27): 81–85.
22. Stuchlíková M, Kantárová D, Michalková D et al. Association of HLA-DPB1 alleleswith type I diabetes mellitus in Slovak population. Bratislavské lekárske listy 2006; 107(3): 73–75.
23. Dedinská I, Miklušica J. Základy pre odbery orgánov a transplantácie obličiek. P + M: Turany 2014. ISBN 978–80–89694–12–9. Dostupné z WWW: <http://portal.jfmed.uniba.sk/clanky.php?aid=271>.
24. Wilkinson A, Davidson J, Dotta F et al. Guidelines for the treatment and management of new-onset diabetes after transplantation. Clin Transplant 2005; 19(3): 291.
25. Vojtková J, Ďurdík P, Michnová Z et al. Exhaled carbonmonoxide in adolescents with diabetic cardiovascular autonomic neuropathy. J Pediatr Endocrinol Metab 2014; 27(7–8): 709–715.
Štítky
Diabetology Endocrinology Internal medicineČlánok vyšiel v časopise
Forum Diabetologicum
2016 Číslo 2
Najčítanejšie v tomto čísle
- Consensual therapeutic algorithm for treatment with insulin pump and continuous monitoring of glucose levels (in compliance with the indicative limitations as amended)
- Consensual therapeutic algorithm for type 2 diabetes mellitus (in accordance with SPC, ADA/EASD indicative limitations and recommendations )
- Kidney transplantation and metabolic syndrome
- Iatrogenic hypoglycemia as a serious medical problem